Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $10.1 million.

  • Kiniksa Pharmaceuticals International's Share-based Compensation rose 2961.92% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.1 million, marking a year-over-year increase of 1623.57%. This contributed to the annual value of $30.7 million for FY2024, which is 1305.39% up from last year.
  • Kiniksa Pharmaceuticals International's Share-based Compensation amounted to $10.1 million in Q3 2025, which was up 2961.92% from $8.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Share-based Compensation high stood at $10.1 million for Q3 2025, and its period low was $5.7 million during Q2 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $6.8 million (2023), whereas its average is $7.1 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Share-based Compensation plummeted by 1536.63% in 2022, and later skyrocketed by 2961.92% in 2025.
  • Kiniksa Pharmaceuticals International's Share-based Compensation (Quarter) stood at $6.1 million in 2021, then rose by 3.93% to $6.4 million in 2022, then rose by 21.99% to $7.8 million in 2023, then rose by 6.75% to $8.3 million in 2024, then rose by 22.25% to $10.1 million in 2025.
  • Its Share-based Compensation was $10.1 million in Q3 2025, compared to $8.9 million in Q2 2025 and $7.7 million in Q1 2025.